Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
24th Annual FIGO Report on the Results of Treatment in Gynaecological Cancer
Since 1937, the Annual Report on the Results of Treatment in Gynaecological Cancer has provided the greatest possible comparability between therapeutic statistics in cancers of the female genital tract, offering gynaecologists and oncologists a reliable resource for the evaluation of different treatment methods. Enhancing even further the Annual Report's value as a source of up-to-date, global, gynaecological cancer-treatment statistics, this volume includes an easy-to-use CD-ROM containing all graphs and charts found in the book.
Surgery in Gynecological Oncology
Gynecological oncology surgery has shown substantial progress in recent years. Most of the advances come from gynecologists with full time commitments to gynecological oncology. Jt is important for the general obstetrician-gynecologist to be informed about the possibilities offered by modern gyneco logical oncology. Thus he or she may acquire new techniques which can be used in general gynecological practice. On the other hand it is essential to know what his or her colleagues, specialised in gynecological oncology can offer in oncology centres. The chapters in this book are based on a post-graduate course organised by the Boerhaave Committee for post-graduate medical education of the medica...
RNA Tumor Viruses, Oncogenes, Human Cancer and AIDS: On the Frontiers of Understanding
We stand today on the threshold of a new understanding of cancer. Primarily through the powerful tools of molecular biology, unified hypotheses explaining the origins of the disease are emerging and rapidly being validated. This volume, which presents the latest findings from laboratories throughout the world on the role of RNA tumor viruses in cancer, is a celebration of these achievements and a prediction of further progress leading ultimately to the control of the disease. It is important in this context to recall the natural history or life cycle of RNA cancer virology. From the earliest days of the science, when viruses were first recognized as distinct biologic agents of etiologic sign...
Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances
Malignant lymphomas remain a fascinating research topic for clinicians as well as basic scientists. Rapidly increasing technical sophistication, ex panded knowledge and broader implications of new findings underline the need for a forum to integrate the latest developments in the multiple areas involved in the challenging study of lymphoid malignancies. This volume includes contributions of renowned experts and is based on a selection of papers presented at the Second International Conference on Malignant Lymphomas that was held in Lugano, Switzerland, in June 1984. Updated information is provided on various experimental fields including cell biolo gy, immunology, genetics and cell biochemis...
Minimal Residual Disease in Acute Leukemia
The objective of the treatment of acute leukemia involves the eradication of all neoplastic cells, including the last one. Ideally, treatment should be controlled by monitoring cell kill. If the last cells could be discovered and their biological properties be determined, the qualitative and quantitative effects of treatment should be directly evaluable. This should ultimately permit a calculated tumor cell reduction thereby avoiding overtreatment and excessive toxicity and thus providing a basis for individualized antileukemic treatment. In recent years several new developments have contributed to the selective discovery of minimal numbers of leukemic cells which are hidden among the normal...
Interferon Alpha-2: Pre-Clinical and Clinical Evaluation
Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus cular and subcutaneous routes. Clinical toxicity principally involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been fo...
Clinical and Experimental Pathology of Lung Cancer
J. G. MCVIE The impact of therapy on one subset of lung cancer, the "small cell" type has been significant and lasting. The reality of cure for even a fraction of patients with this disease has caused reverberations in the pathology lab where the responsibili. '~y and challenge of diagnosis of this vital sub group lies. No less dramatic has been the discovery that the cell types of lung cancer have recognisable growth characteristics in serum free culture, they are recognisable by patterns of markers and some produce growth factors which autoregulate their eventual fate. Many of the discoveries from the biological studies have impacted on the pathologist in the form of disturbing evidence fo...
The Role of Pharmacology in Pediatric Oncology
The dramatic improvement made in recent years in the treatment of child hood malignancies has been in large part the result of advances in the field of pharmacology. Chemotherapy is the major therapeutic modality used to treat childhood cancer. Rational administration of antineoplastic chemo therapy to the child with cancer requires the pediatric oncologist to have a thorough understanding of the fundamental principles of clinical pharmaco logy, an intimate knowledge of the specific agents being used, and an aware ness of the unique biologic and physiologic features of children. In mid 1985, a distinguished group of pediatric oncologists and clinical pharmacologists convened in a unique work...
Minimal Residual Disease in Acute Leukemia 1986
Relapse of leukemia following successful remission-induction therapy remains a major obstacle in the treatment of patients with acute leukemia. Leukemia recurs most frequently in patients with acute myeloblastic leukemia (AML) and high risk acute lymphoblastic leukemia (ALL) following chemotherapy and less often in patients with low risk ALL and particularly in patient groups> submitted to allogeneic marrow transplantation. ' It is likely that the great majority of these recurrences originate from residual leukemic cells that survive initial remission-induction chemotherapy. Today, several research groups throughout the world place emphasis on studies concerned with the detection and treatme...
Monoclonal Antibodies and Breast Cancer
Breast cancer, being a disease with very high prevalence in the female population, has permanently attracted the attention of biologists, biochemists, pathologists, surgeons, and oncologists. In the U.S. alone approximately 120,000 new cases are diagnosed and 37,000 deaths a year are recorded as an outcome. Early diagnosis, clear cut prognosis and the hope of new therapeutic approaches has spurred the enthusiasm of researchers, who with the advent of newer methodologies, tried to employ it in different approaches to the breast cancer patient. In spite of the efforts devoted towards the creation of new approaches, reagents and procedures taking advantage of special characteristics of the brea...
